J Alan Diehl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2324717/publications.pdf

Version: 2024-02-01

147 17,882 68 130 papers citations h-index g-index

196 196 196 25919 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma. Gut, 2022, 71, 665-675.	6.1	15
2	Non-phosphorylatable cyclin D1 mutant potentiates endometrial hyperplasia and drives carcinoma with Pten loss. Oncogene, 2022, 41, 2187-2195.	2.6	4
3	Ubiquitylation of unphosphorylated c-myc by novel E3 ligase SCF ^{Fbxl8} . Cancer Biology and Therapy, 2022, 23, 348-357.	1.5	2
4	Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors. Nature Cancer, 2022, 3, 808-820.	5.7	21
5	A stromal Integrated Stress Response activates perivascular cancer-associated fibroblasts to drive angiogenesis and tumour progression. Nature Cell Biology, 2022, 24, 940-953.	4.6	52
6	Fbxl8 suppresses lymphoma growth and hematopoietic transformation through degradation of cyclin D3. Oncogene, 2021, 40, 292-306.	2.6	13
7	The Structure, Activation and Signaling of IRE1 and Its Role in Determining Cell Fate. Biomedicines, 2021, 9, 156.	1.4	58
8	Mutant p53 regulates Survivin to foster lung metastasis. Genes and Development, 2021, 35, 528-541.	2.7	19
9	The AMBRA1 E3 ligase adaptor regulates the stability of cyclinÂD. Nature, 2021, 592, 794-798.	13.7	76
10	Regulation of intercellular biomolecule transfer $\hat{a} \in \text{``driven tumor angiogenesis'}$ and responses to anticancer therapies. Journal of Clinical Investigation, 2021, 131, .	3.9	11
11	Alcohol Metabolism Enriches Squamous Cell Carcinoma Cancer Stem Cells That Survive Oxidative Stress via Autophagy. Biomolecules, 2021, 11, 1479.	1.8	10
12	Cyclin D degradation by E3 ligases in cancer progression and treatment. Seminars in Cancer Biology, 2020, 67, 159-170.	4.3	37
13	Activation of p38 $\hat{l}\pm$ stress-activated protein kinase drives the formation of the pre-metastatic niche in the lungs. Nature Cancer, 2020, 1, 603-619.	5.7	33
14	The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases. International Journal of Molecular Sciences, 2020, 21, 2108.	1.8	45
15	Generation and Characterization of Patientâ€Derived Head and Neck, Oral, and Esophageal Cancer Organoids. Current Protocols in Stem Cell Biology, 2020, 53, e109.	3.0	45
16	Use of Small-molecule Inhibitory Compound of PERK-dependent Signaling Pathway as a Promising Target-based Therapy for Colorectal Cancer. Current Cancer Drug Targets, 2020, 20, 223-238.	0.8	7
17	Structural insights into E1 recognition and the ubiquitin-conjugating activity of the E2 enzyme Cdc34. Nature Communications, 2019, 10, 3296.	5.8	39
18	ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression. Nature Cell Biology, 2019, 21, 889-899.	4.6	157

#	Article	IF	CITATIONS
19	Dual role of Endoplasmic Reticulum Stress-Mediated Unfolded Protein Response Signaling Pathway in Carcinogenesis. International Journal of Molecular Sciences, 2019, 20, 4354.	1.8	96
20	SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. Science Advances, 2019, 5, eaax6352.	4.7	31
21	Glutamine addiction: an Achilles heel in esophageal cancers with dysregulation of CDK4/6. Molecular and Cellular Oncology, 2019, 6, 1610257.	0.3	5
22	Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. Nature Communications, 2019, 10, 1296.	5.8	73
23	The PKR-Like Endoplasmic Reticulum Kinase Promotes the Dissemination of Myc-Induced Leukemic Cells. Molecular Cancer Research, 2019, 17, 1450-1458.	1.5	5
24	An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. Cancer Cell, 2019, 35, 33-45.e6.	7.7	125
25	Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 73-91.	2.3	102
26	Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment. Current Medicinal Chemistry, 2019, 26, 1425-1445.	1.2	10
27	The Long (lncRNA) and Short (miRNA) of lt: $TGF\hat{l}^2$ -Mediated Control of RNA-Binding Proteins and Noncoding RNAs. Molecular Cancer Research, 2018, 16, 567-579.	1.5	61
28	A PERK–miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival. Nature Cell Biology, 2018, 20, 104-115.	4.6	86
29	Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9298-E9307.	3.3	91
30	Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nature Medicine, 2018, 24, 968-977.	15.2	196
31	IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment. Cancer Research, 2018, 78, 4957-4970.	0.4	203
32	MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer. Clinical Cancer Research, 2018, 24, 4201-4214.	3.2	77
33	BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in <i>Kras</i> -Mutant Non–Small Cell Lung Cancer. Cancer Immunology Research, 2018, 6, 1234-1245.	1.6	80
34	CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. Nature Communications, 2017, 8, 13897.	5.8	54
35	Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell, 2017, 31, 194-207.	7.7	179
36	Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2. Nature Communications, 2017, 8, 14922.	5.8	80

#	Article	IF	CITATIONS
37	HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via \hat{l}^2 -Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation. American Journal of Pathology, 2017, 187, 91-109.	1.9	29
38	A regulated PNUTS mRNA to IncRNA splice switch mediates EMT and tumour progression. Nature Cell Biology, 2017, 19, 1105-1115.	4.6	262
39	Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma. Nature Communications, 2017, 8, 1758.	5.8	155
40	Fbxo4-mediated degradation of Fxr1 suppresses tumorigenesis in head and neck squamous cell carcinoma. Nature Communications, 2017, 8, 1534.	5.8	42
41	Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines. PLoS ONE, 2017, 12, e0177830.	1.1	17
42	Recent insights into PERK-dependent signaling from the stressed endoplasmic reticulum. F1000Research, 2017, 6, 1897.	0.8	75
43	CNPY2 is a key initiator of the PERK–CHOP pathway of the unfolded protein response. Nature Structural and Molecular Biology, 2017, 24, 834-839.	3.6	42
44	Molecular Basis of Human Diseases and Targeted Therapy Based on Small-Molecule Inhibitors of ER Stress-Induced Signaling Pathways. Current Molecular Medicine, 2017, 17, 118-132.	0.6	17
45	Inhibition of PERK-dependent pro-adaptive signaling pathway as a promising approach for cancer treatment. Polski Przeglad Chirurgiczny, 2017, 89, 7-10.	0.2	4
46	RNA-Binding Protein FXR1 Regulates p21 and TERC RNA to Bypass p53-Mediated Cellular Senescence in OSCC. PLoS Genetics, 2016, 12, e1006306.	1.5	52
47	PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma. PLoS Genetics, 2016, 12, e1006518.	1.5	41
48	Stressing out melanoma with an antiâ€ <scp>GRP</scp> 78 compound. Pigment Cell and Melanoma Research, 2016, 29, 490-491.	1.5	3
49	PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development. Journal of Cellular Physiology, 2016, 231, 2088-2096.	2.0	60
50	Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6. Cancer Research, 2016, 76, 2990-3002.	0.4	123
51	Cyclin D1, cancer progression, and opportunities in cancer treatment. Journal of Molecular Medicine, 2016, 94, 1313-1326.	1.7	477
52	Cyclin D3: To translate or not to translate. Cell Cycle, 2016, 15, 3018-3019.	1.3	2
53	miR-216b regulation of c-Jun mediates GADD153/CHOP-dependent apoptosis. Nature Communications, 2016, 7, 11422.	5.8	71
54	The role of the Amyloid Precursor Protein mutations and PERKdependent signaling pathways in the pathogenesis of Alzheimer's disease. Acta Universitatis Lodziensis Folia Biologica Et Oecologica, 2016, 12, 48-59.	1.0	1

#	Article	IF	CITATIONS
55	Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression. Cell Reports, 2016, 15, 171-180.	2.9	83
56	Selective Vulnerability of Cancer Cells by Inhibition of Ca2+ Transfer from Endoplasmic Reticulum to Mitochondria. Cell Reports, 2016, 14, 2313-2324.	2.9	195
57	Type I interferons mediate pancreatic toxicities of PERK inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15420-15425.	3.3	52
58	PRMT5 Is Required for Lymphomagenesis Triggered by Multiple Oncogenic Drivers. Cancer Discovery, 2015, 5, 288-303.	7.7	127
59	FBXO4 loss facilitates carcinogen induced papilloma development in mice. Cancer Biology and Therapy, 2015, 16, 750-755.	1.5	23
60	HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma. Cancer Discovery, 2015, 5, 652-667.	7.7	278
61	Molecular Pathways: The PERKs and Pitfalls of Targeting the Unfolded Protein Response in Cancer. Clinical Cancer Research, 2015, 21, 675-679.	3.2	27
62	ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes metastasis. Journal of Clinical Investigation, 2015, 125, 2592-2608.	3.9	210
63	PRMT5-dependent p53 escape in tumorigenesis. Oncoscience, 2015, 2, 700-702.	0.9	10
64	CDK4/6 inhibitor: from quiescence to senescence. Oncoscience, 2015, 2, 896-897.	0.9	15
65	Unfolded Protein Response and PERK Kinase as a New Therapeutic Target in the Pathogenesis of Alzheimer's Disease. Current Medicinal Chemistry, 2015, 22, 3169-3184.	1.2	61
66	Generation and characterization of an analog-sensitive PERK allele. Cancer Biology and Therapy, 2014, 15, 1106-1111.	1.5	3
67	Enzymatic Characterization of ER Stress-Dependent Kinase, PERK, and Development of a High-Throughput Assay for Identification of PERK Inhibitors. Journal of Biomolecular Screening, 2014, 19, 1024-1034.	2.6	21
68	IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment. American Journal of Cancer Research, 2014, 4, 29-41.	1.4	50
69	UPR-inducible miRNAs contribute to stressful situations. Trends in Biochemical Sciences, 2013, 38, 447-452.	3.7	47
70	EGFR Inhibition Promotes an Aggressive Invasion Pattern Mediated by Mesenchymal-like Tumor Cells within Squamous Cell Carcinomas. Molecular Cancer Therapeutics, 2013, 12, 2176-2186.	1.9	23
71	The ζ Isoform of Diacylglycerol Kinase Plays a Predominant Role in Regulatory T Cell Development and TCR-Mediated Ras Signaling. Science Signaling, 2013, 6, ra102.	1.6	57
72	Regulation of autophagy during ECM detachment is linked to a selective inhibition of mTORC1 by PERK. Oncogene, 2013, 32, 4932-4940.	2.6	132

#	Article	IF	CITATIONS
73	The FBXO4 Tumor Suppressor Functions as a Barrier to Braf ^{V600E} -Dependent Metastatic Melanoma. Molecular and Cellular Biology, 2013, 33, 4422-4433.	1.1	32
74	Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress. Genes and Development, 2013, 27, 1115-1131.	2.7	170
75	Identification and Characterization of a Potent Activator of p53-Independent Cellular Senescence via a Small-Molecule Screen for Modifiers of the Integrated Stress Response. Molecular Pharmacology, 2013, 83, 594-604.	1.0	12
76	A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion. Cancer Biology and Therapy, 2013, 14, 853-859.	1.5	33
77	PERK Utilizes Intrinsic Lipid Kinase Activity To Generate Phosphatidic Acid, Mediate Akt Activation, and Promote Adipocyte Differentiation. Molecular and Cellular Biology, 2012, 32, 2268-2278.	1.1	97
78	PERK Is Required in the Adult Pancreas and Is Essential for Maintenance of Glucose Homeostasis. Molecular and Cellular Biology, 2012, 32, 5129-5139.	1.1	92
79	Adenomatous Polyposis Coli (APC) Regulates Multiple Signaling Pathways by Enhancing Glycogen Synthase Kinase-3 (GSK-3) Activity. Journal of Biological Chemistry, 2012, 287, 3823-3832.	1.6	74
80	ER stress–mediated autophagy promotes Myc-dependent transformation and tumor growth. Journal of Clinical Investigation, 2012, 122, 4621-4634.	3.9	336
81	miR-211 Is a Prosurvival MicroRNA that Regulates chop Expression in a PERK-Dependent Manner. Molecular Cell, 2012, 48, 353-364.	4.5	192
82	Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. Journal of Clinical Investigation, 2012, 122, 241-252.	3.9	157
83	The Cell Biology of the Unfolded Protein Response. Gastroenterology, 2011, 141, 38-41.e2.	0.6	91
84	HIV-1 Vif promotes the G1- to S-phase cell-cycle transition. Blood, 2011, 117, 1260-1269.	0.6	28
85	Deletion of p120-Catenin Results in a Tumor Microenvironment with Inflammation and Cancer that Establishes It as a Tumor Suppressor Gene. Cancer Cell, 2011, 19, 470-483.	7.7	176
86	PERK Integrates Autophagy and Oxidative Stress Responses To Promote Survival during Extracellular Matrix Detachment. Molecular and Cellular Biology, 2011, 31, 3616-3629.	1.1	243
87	The Fbx4 Tumor Suppressor Regulates Cyclin D1 Accumulation and Prevents Neoplastic Transformation. Molecular and Cellular Biology, 2011, 31, 4513-4523.	1.1	45
88	A NOTCH3-Mediated Squamous Cell Differentiation Program Limits Expansion of EMT-Competent Cells That Express the ZEB Transcription Factors. Cancer Research, 2011, 71, 6836-6847.	0.4	99
89	Role of p38 Protein Kinase in the Ligand-independent Ubiquitination and Down-regulation of the IFNAR1 Chain of Type I Interferon Receptor. Journal of Biological Chemistry, 2011, 286, 22069-22076.	1.6	40
90	Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle, 2011, 10, 2008-2016.	1.3	51

#	Article	IF	Citations
91	Nuclear Cyclin D1/CDK4 Kinase Regulates CUL4 Expression and Triggers Neoplastic Growth via Activation of the PRMT5 Methyltransferase. Cancer Cell, 2010, 18, 329-340.	7.7	205
92	The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO Journal, 2010, 29, 2082-2096.	3.5	535
93	Epidermal Growth Factor Receptor and Mutant p53 Expand an Esophageal Cellular Subpopulation Capable of Epithelial-to-Mesenchymal Transition through ZEB Transcription Factors. Cancer Research, 2010, 70, 4174-4184.	0.4	128
94	Periostin, a Cell Adhesion Molecule, Facilitates Invasion in the Tumor Microenvironment and Annotates a Novel Tumor-Invasive Signature in Esophageal Cancer. Cancer Research, 2010, 70, 5281-5292.	0.4	103
95	Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11026-11031.	3.3	160
96	Inducible Priming Phosphorylation Promotes Ligand-independent Degradation of the IFNAR1 Chain of Type I Interferon Receptor. Journal of Biological Chemistry, 2010, 285, 2318-2325.	1.6	41
97	Insulin-like growth factor-binding protein-3 promotes transforming growth factor- \hat{l}^21 -mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells. Carcinogenesis, 2010, 31, 1344-1353.	1.3	72
98	Ubiquitin-Dependent Proteolysis in G1/S Phase Control and Its Relationship with Tumor Susceptibility. Genes and Cancer, 2010, $1,717-724$.	0.6	16
99	Ubiquitin and Cancer: New Discussions for a New Journal. Genes and Cancer, 2010, 1, 679-680.	0.6	8
100	Structural Basis of Selective Ubiquitination of TRF1 by SCFFbx4. Developmental Cell, 2010, 18, 214-225.	3.1	55
101	DNA damage-dependent cyclin D1 proteolysis: GSK3β holds the smoking gun. Cell Cycle, 2009, 8, 824-827.	1.3	23
102	Cyclin D2 Protein Stability Is Regulated in Pancreatic \hat{l}^2 -Cells. Molecular Endocrinology, 2009, 23, 1865-1875.	3.7	45
103	Nuclear cyclin D1: An oncogenic driver in human cancer. Journal of Cellular Physiology, 2009, 220, 292-296.	2.0	375
104	Virus-Induced Unfolded Protein Response Attenuates Antiviral Defenses via Phosphorylation-Dependent Degradation of the Type I Interferon Receptor. Cell Host and Microbe, 2009, 5, 72-83.	5.1	118
105	Mutations in Fbx4 Inhibit Dimerization of the SCFFbx4 Ligase and Contribute to Cyclin D1 Overexpression in Human Cancer. Cancer Cell, 2008, 14, 68-78.	7.7	135
106	Hypoxic Reactive Oxygen Species Regulate the Integrated Stress Response and Cell Survival. Journal of Biological Chemistry, 2008, 283, 31153-31162.	1.6	174
107	PERK-dependent regulation of lipogenesis during mouse mammary gland development and adipocyte differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16314-16319.	3.3	228
108	Genotoxic Stress-Induced Cyclin D1 Phosphorylation and Proteolysis Are Required for Genomic Stability. Molecular and Cellular Biology, 2008, 28, 7245-7258.	1.1	64

#	Article	IF	CITATIONS
109	Phosphorylation of MCM3 on Ser-112 regulates its incorporation into the MCM2–7 complex. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8079-8084.	3.3	48
110	SCFFbx4/αB-crystallin E3 ligase: When one is not enough. Cell Cycle, 2008, 7, 2983-2986.	1.3	36
111	Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Molecular Cancer Therapeutics, 2008, 7, 2866-2875.	1.9	66
112	A subpopulation of mouse esophageal basal cells has properties of stem cells with the capacity for self-renewal and lineage specification. Journal of Clinical Investigation, 2008, 118, 3860-9.	3.9	113
113	Cell Cycle–Dependent and Schedule-Dependent Antitumor Effects of Sorafenib Combined with Radiation. Cancer Research, 2007, 67, 9443-9454.	0.4	125
114	Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Genes and Development, 2007, 21, 2908-2922.	2.7	115
115	Coping with Stress: ATF6α Takes the Stage. Developmental Cell, 2007, 13, 322-324.	3.1	5
116	HIF-2 \hat{l}_{\pm} Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional Activity. Cancer Cell, 2007, 11, 335-347.	7.7	702
117	Coordination of ER and oxidative stress signaling: The PERK/Nrf2 signaling pathway. International Journal of Biochemistry and Cell Biology, 2006, 38, 317-332.	1.2	499
118	Phosphorylation-Dependent Ubiquitination of Cyclin D1 by the SCFFBX4-αB Crystallin Complex. Molecular Cell, 2006, 24, 355-366.	4.5	321
119	Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene, 2006, 25, 1620-1628.	2.6	332
120	Mutation of Tumor Suppressor Gene Men1 Acutely Enhances Proliferation of Pancreatic Islet Cells. Cancer Research, 2006, 66, 5707-5715.	0.4	108
121	Ribosomal Stress Couples the Unfolded Protein Response to p53-dependent Cell Cycle Arrest. Journal of Biological Chemistry, 2006, 281, 30036-30045.	1.6	105
122	A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene, 2005, 24, 431-444.	2.6	63
123	Location, location, location: The role of cyclin D1 nuclear localization in cancer. Journal of Cellular Biochemistry, 2005, 96, 906-913.	1.2	124
124	Cyclin D1 and Pancreatic Carcinoma: A Proliferative Agonist and Chemotherapeutic Antagonist: Fig. 1 Clinical Cancer Research, 2005, 11, 5665-5667.	3.2	14
125	PERK and GCN2 Contribute to eIF2α Phosphorylation and Cell Cycle Arrest after Activation of the Unfolded Protein Response Pathway. Molecular Biology of the Cell, 2005, 16, 5493-5501.	0.9	226
126	Retinoid Targeting of Different D-Type Cyclins through Distinct Chemopreventive Mechanisms. Cancer Research, 2005, 65, 6476-6483.	0.4	31

#	Article	IF	CITATIONS
127	C-terminal Sequences Direct Cyclin D1-CRM1 Binding. Journal of Biological Chemistry, 2004, 279, 56061-56066.	1.6	36
128	The Keap1-BTB Protein Is an Adaptor That Bridges Nrf2 to a Cul3-Based E3 Ligase: Oxidative Stress Sensing by a Cul3-Keap1 Ligase. Molecular and Cellular Biology, 2004, 24, 8477-8486.	1.1	858
129	Cyclin-Dependent Kinase Inhibition by the KLF6 Tumor Suppressor Protein through Interaction with Cyclin D1. Cancer Research, 2004, 64, 3885-3891.	0.4	152
130	The Cyclin D3 Knockout: A Pound of Redundancy with a Dash of Tissue Specificity. Cancer Biology and Therapy, 2004, 3, 162-164.	1.5	6
131	PERK-dependent Activation of Nrf2 Contributes to Redox Homeostasis and Cell Survival following Endoplasmic Reticulum Stress. Journal of Biological Chemistry, 2004, 279, 20108-20117.	1.6	612
132	Mechanism of cell-cycle control: ligating the ligase. Trends in Biochemical Sciences, 2004, 29, 453-455.	3.7	7
133	Cell cycle progression without cyclin E/CDK2. Cancer Cell, 2003, 4, 160-162.	7.7	62
134	GATA-1-Mediated Proliferation Arrest during Erythroid Maturation. Molecular and Cellular Biology, 2003, 23, 5031-5042.	1.1	186
135	Hsc70 Regulates Accumulation of Cyclin D1 and Cyclin D1-Dependent Protein Kinase. Molecular and Cellular Biology, 2003, 23, 1764-1774.	1.1	88
136	Nrf2 Is a Direct PERK Substrate and Effector of PERK-Dependent Cell Survival. Molecular and Cellular Biology, 2003, 23, 7198-7209.	1.1	1,074
137	The Cyclin D1-dependent Kinase Associates with the Pre-replication Complex and Modulates RB·MCM7 Binding. Journal of Biological Chemistry, 2003, 278, 9754-9760.	1.6	72
138	An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Research, 2003, 63, 7056-61.	0.4	190
139	Cycling to Cancer with Cyclin D1. Cancer Biology and Therapy, 2002, 1, 226-231.	1.5	427
140	p21Cip1 Promotes Cyclin D1 Nuclear Accumulation via Direct Inhibition of Nuclear Export. Journal of Biological Chemistry, 2002, 277, 8517-8523.	1.6	176
141	Translation Mediated by the Internal Ribosome Entry Site of the cat-1 mRNA Is Regulated by Glucose Availability in a PERK Kinase-dependent Manner. Journal of Biological Chemistry, 2002, 277, 11780-11787.	1.6	78
142	Two Distinct Stress Signaling Pathways Converge Upon the CHOP Promoter During the Mammalian Unfolded Protein Response. Journal of Molecular Biology, 2002, 318, 1351-1365.	2.0	605
143	Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes and Development, 2000, 14, 3102-3114.	2.7	476
144	A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2. Oncogene, 1999, 18, 573-582.	2.6	94

J Alan Diehl

#	Article	IF	CITATIONS
145	Involvement of lipid mediators on cytokine signaling and induction of secretory phospholipase A2 in immortalized astrocytes (DITNC). Journal of Molecular Neuroscience, 1999, 12, 89-99.	1.1	20
146	A threshold nuclear level of the v-Rel oncoprotein is required for transformation of avian lymphocytes. Oncogene, 1997, 14, 2585-2594.	2.6	13
147	Tumor Necrosis Factor- $\hat{l}\pm$ -dependent Activation of a RelA Homodimer in Astrocytes. Journal of Biological Chemistry, 1995, 270, 2703-2707.	1.6	52